Research
Tumors shrank in 11 of 25 people with advanced pancreatic cancer on an experimental RAS pill
PANCREATIC CANCER is usually diagnosed after it has already spread, and only 15% to 20% of people are eligible for surgery at diagnosis. Five-year survival has improved from 4% in the mid-1990s to 13%, among the lowest of all cancer types. The most common form, accounting for over 90% of pancreatic tumors, is pancreatic ductal adenocarcinoma.
A protein called RAS acts as a growth switch inside cells. In nearly all of these tumors the switch is stuck in the "on" position, so it keeps sending growth signals. In a database of 7,407 people with this cancer, 99% of RAS mutations were in the gene that makes this protein, KRAS. Most of those changes alter the same spot in the protein, position 12, and tumors that carry one are grouped together as KRAS G12X.
A drug that hit every form of RAS was long expected to be too toxic. One newer approach uses a molecule that brings proteins together so that growth signals from several different RAS mutations are blocked, binding RAS while the switch is in the "on" state. A medicine that works this way is a pan-RAS molecular glue. Erasca is testing a daily pill of this class, ERAS-0015, in an early study called AURORAS-1. Today's briefing covered Revolution Medicines' daraxonrasib, another pill that blocks RAS, now approved in the United States after earlier treatment for metastatic pancreatic cancer.
AURORAS-1 began in June 2025. It is a Phase 1 trial, the first stage of human testing. People are not assigned by chance to different treatments. The study has no comparison group. Doses started at 2 mg once daily and rose as high as 40 mg, with each new group given a higher dose in order to find a safe one, a design called dose escalation. On November 20th, 2026, Dr Judy Wang, a medical oncologist at Florida Cancer Specialists and Research Institute, presented results at the 38th EORTC-NCI-AACR Symposium in Barcelona. The symposium organizers' release says the presentation covered 148 people, with results for 83 with pancreatic cancer and 37 with lung cancer, a cancer the trial also includes. Median follow-up was just over four months, with no sign that the highest safe dose had been reached.
The main figure reported is the share of people whose tumors shrink by a set amount on scans, an objective response, counted only when that shrinkage is seen again on a later scan, and so is confirmed. At 32 mg once daily, 11 of 25 people with KRAS G12X pancreatic cancer (44%) had a confirmed response by the time of the presentation. All 25 had already received at least one earlier treatment for advanced disease. All 11 people with a confirmed response were still taking the pill.
An Erasca filing dated November 20, 2026, reports safety in 122 people given at least one dose at 16 to 32 mg once daily, as of September 1, 2026. The most common drug-related side effects were rash in 99 of 122, diarrhea in 39 of 122, nausea in 29 of 122, and mouth sores, or stomatitis, in 26 of 122. The symposium organizers' release says 12 patients (9.8%) had severe, grade 3 or higher, drug-related side effects. At the 32 mg dose, among 54 people, drug-related effects led to a pause in 7 of 54, a dose cut in 9 of 54, and a stop in none. A 66-year-old man with heavily pretreated pancreatic cancer given 24 mg developed severe lung inflammation (pneumonitis) about a month after starting and died after supportive care was withdrawn at his request, a death Erasca first disclosed in April 2026.
Because the study had no comparison group, it cannot show that the pill helps people live longer or that it beats existing treatment. Tumor shrinkage is not the same as living longer, and follow-up so far is about four months. Professor Elena Garralda, chair of the symposium, is based at the Vall d'Hebron Institute of Oncology and was not involved with the study. She said, "We look forward to further results from larger clinical trials, which are investigating whether ERAS-0015 can help a broader group of patients."
Erasca is also testing ERAS-0015 with a standard chemotherapy pair, gemcitabine plus nab-paclitaxel, and says efficacy data from that combination are not yet available. The company plans to start a controlled Phase 3 trial in previously untreated pancreatic cancer in the first half of 2027.